FDA approval for over-the-counter sales of a pharmaceutical product typically leads to increased product visibility, accessibility, and sales. Given the ongoing opioid crisis in the United States, the demand for easily accessible overdose treatments like Naloxone is high. This approval positions Amneal Pharmaceuticals favorably in the market, likely leading to positive investor sentiment and a potential increase in stock price in the short term.